Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes promising clinical assets, but sentiment towards the stock is mixed and price structure has broken down. Updates from its major clinical programs are the key drivers to equity returns for MRUS at this stage in its lifecycle.

Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an underwritten public offering of 6,818,182 common shares, at a public offering price of $22.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 1,022,727 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $150.0 million. All of the shares in the offering are to be sold by Merus.

Merus Announces Pricing of Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Merus N.V. Announces Proposed Public Offering of Common Shares

Merus N.V. (MRUS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.13 per share a year ago.

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma

Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced two abstracts were selected for presentation at the European Society for Medical Oncology Congress (ESMO) 2023.

Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023

– Zeno granted BTD for the treatment of NRG1+ non-small cell lung cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Merus N.V.

Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration

Shares of Merus NV MRUS, +3.02% rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administration has granted one of its cancer treatments a breakthrough therapy designation, intended for expedite the development and review of a drug to treat serious illness. The drug, zenocutuzumab, is geared to the treatment of patients with a type of advanced, metastatic pancreatic cancer.

Merus stock jumps 10% after FDA's action on cancer drug

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for zenocutuzumab (Zeno) for the treatment of patients with advanced unresectable or metastatic NRG1 fusion (NRG1+) pancreatic cancer following progression with prior systemic therapy or who have no satisfactory alternative treatment options. This designation for Zeno follows a Fast Track Designation for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions (NRG1+ cancer) that have progressed on standard of care therapy on January 7, 2021 and Orphan Drug Designation for the treatment of patients with pancreatic cancer on July 27, 2020.

Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors.

Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

Darling Ingredients

Tenet Healthcare

Viking Therapeutics

Chemed

Lantheus Holdings

Carrols Restaurant Group

Stock screeners can help investors identify stocks to buy based on a variety of criteria. In fact, one helpful predictor of stock price growth can be found with analyst ratings.

7 Stocks That Wall Street Analysts Are Loving in May

Does Merus N.V. (MRUS) have what it takes to be a top stock pick for momentum investors?

Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy

The consensus price target hints at an 114.6% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to Trade

Merus N.V. (MRUS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.43 per share a year ago.

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

– Petosemtamab clinical update presented at the American Association of Cancer Research (AACR) Annual Meeting 2023 – Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in head and neck squamous cell carcinoma (HNSCC) – Petosemtamab update planned for Q3 2023 on potential registrational path in HNSCC – Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into second half 2025

Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for

- 37% overall response rate (ORR) observed in 43 evaluable patients- 6 months median duration of response as of Feb. 1, 2023 data cutoff date- End-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC- Investor call on April 17, 2023 at 6:30 p.m. ET

Merus' Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)

- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC - Investor call on April 17, 2023 at 6:30 p.m. ET ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.

Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract for a poster presentation of early clinical data on the bispecific antibody petosemtamab in advanced gastric/esophageal adenocarcinoma (GEA) at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place in Orlando, Florida April 14-19, 2023.

Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023

Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma.

Merus: Dutch Drug Developer With An Interesting Platform

Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET

Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023

– Plenary session oral presentation: Monday, April 17, 2023, 10:15 a.m.-12:15 p.m. ET– Poster presentation on petosemtamab in advanced gastric/esophageal adenocarcinoma: Monday, April 17, 2023, 1:30-5:30 p.m. ET– Investor call on Monday, April 17, 2023 at 6:30 p.m. ET

Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023

– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023

Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update

Merus (MRUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Merus (MRUS) This Earnings Season?

Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Merus Stock (MRUS)